Your session is about to expire
← Back to Search
Calcium Channel Blocker
Topical diltiazem + lidocaine for Rectal Disease
Phase 2 & 3
Waitlist Available
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
This trial is testing two creams, Diltiazem and Nifedipine, on patients with long-lasting anal tears. These creams help by relaxing the muscles around the tear, allowing better blood flow and faster healing.
Eligible Conditions
- Rectal Disease
- Nipple Injury
- Anal Fissure
- Rectal Bleeding
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Anal bleeding
Perianal irritation
Perianal pain
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Topical diltiazem + lidocaineExperimental Treatment1 Intervention
Group II: Topical nifedipine + lidocaineActive Control1 Intervention
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
808 Previous Clinical Trials
883,959 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger